<code id='157BE84394'></code><style id='157BE84394'></style>
    • <acronym id='157BE84394'></acronym>
      <center id='157BE84394'><center id='157BE84394'><tfoot id='157BE84394'></tfoot></center><abbr id='157BE84394'><dir id='157BE84394'><tfoot id='157BE84394'></tfoot><noframes id='157BE84394'>

    • <optgroup id='157BE84394'><strike id='157BE84394'><sup id='157BE84394'></sup></strike><code id='157BE84394'></code></optgroup>
        1. <b id='157BE84394'><label id='157BE84394'><select id='157BE84394'><dt id='157BE84394'><span id='157BE84394'></span></dt></select></label></b><u id='157BE84394'></u>
          <i id='157BE84394'><strike id='157BE84394'><tt id='157BE84394'><pre id='157BE84394'></pre></tt></strike></i>

          explore

          explore

          author:entertainment    Page View:7
          An light blue number 3 with an eye is surrounded by smaller, black number 3s on an orange background — 3 to watch coverage from STAT
          Christine Kao/STAT

          It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was hard to come by, and valuations were down. On the policy side, the industry grappled with changing AI regulations, reimbursement woes, and device sterilization rules.

          Here are three political and market forces that shaped the medtech industry last year, and are worth paying attention to in 2024:

          advertisement

          Lobbying power of AI, software-enabled devices

          Medtech lobby AdvaMed announced earlier this month that the major medical imaging companies, previously housed within the National Electrical Manufacturers Association, were shifting to their shop. The device group also created a separate niche for digital health companies in October.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated
          Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

          ThisistheonlineeditionofAdam’sBiotechScorecard,anewsubscriber-onlynewsletter.STAT+subscriberscansign

          read more
          New air purifier tech could be key to improving indoor air quality
          New air purifier tech could be key to improving indoor air quality

          AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

          read more

          Obesity drug from Roche shows promise in early study

          SebastienBozon/AFPviaGettyImagesLONDON—RocheonThursdaysaiditsrecentlyacquiredexperimentalobesitymedi